CoChat

Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin V ascular Adverse Lesions ( REMOVAL ): An international multicentre trial

Open access
Petrie, John R., Chaturvedi, Nish, Ford, Ian, Hramiak, Irene, Hughes, Alun D., Jenkins, Alicia J., E. Klein, Barbara, Klein, Ron, Ooi, Teik Chye, Rossing, Peter, Sattar, Naveed, Stehouwer, Coen D. A., Colhoun, Helen M., on behalf of the REMOVAL Trial Team · 2017 · Diabetes, Obesity and Metabolism
Cited by 39

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Aims: Cardiovascular ( CV ) disease is a major cause of reduced life expectancy in type 1 diabetes ( T1D ). Intensive insulin therapy prevents CV complications but is constrained by hypoglycaemia and weight gain. Adjunct metformin reduces insulin dose requirement and stabilizes weight but there are no data on its cardiovascular effects. We have therefore initiated an international double‐blind, randomized, placebo‐controlled trial ( REMOVAL : REducing with MetfOrmin V ascular A dverse L esions in type 1 diabetes) to examine whether metformin reduces progression of atherosclerosis in adults with T1D . Individuals ≥40 years of age with T1D for ≥5 years are eligible if they have ≥3 of 10 specified CV risk factors. The enrolment target is 500 participants in 17 international centres. Materials and methods: After 12 weeks of single‐blind placebo‐controlled run‐in, participants with ≥ 70% adherence are randomized to metformin or matching placebo for 3 years with insulin titrated towards HbA1c 7.0% (53 mmol/mol). The primary endpoint is progression of averaged mean far wall common carotid intima‐media thickness ( cIMT ) measured by ultrasonography at baseline, 12, 24 and 36 months. This design provides 90% power to detect a mean difference of 0.0167 mm in cIMT progression between treatment arms (α = 0.05), assuming that up to 20% withdraw or discontinue treatment. Other endpoints include HbA1c , weight, LDL cholesterol, insulin requirement, progression of retinopathy, endothelial function and frequency of hypoglycaemia. Conclusion: REMOVAL is the largest clinical trial of adjunct metformin therapy in T1D to date and will provide clinically meaningful information on its potential to impact CV disease and other complications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12840

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 39

Metadata

Authors
Petrie, J. R., Chaturvedi, N., Ford, I., Hramiak, I., Hughes, A. D., Jenkins, A. J., E. Klein, B., Klein, R., Ooi, T. C., Rossing, P., Sattar, N., Stehouwer, C. D. A., Colhoun, H. M., & on behalf of the REMOVAL Trial Team
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-02-17
Volume
19
Issue
4
Pages
509-516
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2563196695
Cited by
39
References
19
FWCI
4.33
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.